Rapid, point-of-care (POC) diagnostics are essential to mitigate the impacts of current
(and future) epidemics; however, current methods for detecting severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) require complicated laboratory tests that are
generally conducted off-site and require substantial time. CRISPR-Cas systems have been
harnessed to develop sensitive and specific platforms for nucleic acid detection. These
detection platforms take advantage of CRISPR enzymes’ RNA-guided specificity for
RNA and DNA targets and collateral trans activities on single-stranded RNA and DNA
reporters. Microbial genomes possess an extensive range of CRISPR enzymes with different
specificities and levels of collateral activity; identifying new enzymes may improve
CRISPR-based diagnostics. Here, we identified a new Cas13 variant, which we named as
miniature Cas13 (mCas13), and characterized its catalytic activity. We then employed
this system to design, build, and test a SARS-CoV-2 detection module coupling reverse
transcription loop-mediated isothermal amplification (RT-LAMP) with the mCas13 system to
detect SARS-CoV-2 in synthetic and clinical samples. Our system exhibits sensitivity and
specificity comparable to other CRISPR systems. This work expands the repertoire and
application of Cas13 enzymes in diagnostics and for potential
in vivo
applications, including RNA knockdown and editing. Importantly, our system can be
potentially adapted and used in large-scale testing for diverse pathogens, including RNA
and DNA viruses, and bacteria.